Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509845 | 0.85 | HPGD (0.58) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18570098 | 0.84 | HSP90AA1 (0.64) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL471668 | 0.82 | HPGD (0.51) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4472813 | 0.82 | HPGD (0.51) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17877022 | 0.82 | HPGD (0.53) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1034975 | 0.82 | HPGD (0.49) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12677875 | 0.82 | HPGD (0.51) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6648687 | 0.82 | ALDH1A1 (0.51) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10082156 | 0.82 | USP2 (0.57) | HPGDTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7225379 | 0.82 | HPGD (0.49) | HPGDTDP1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220386582-A1 | METHOD AND DEVICE TO TRAP ACARIDS | DOMOBIOS (BE) | 2022-12-08 | — | — | US | disclosed |
| US-20210161130-A1 | COMPOSITIONS FOR ATTRACTING PESTS AND USES THEREOF | DOMOBIOS (BE) | 2021-06-03 | — | — | US | disclosed |
| EP-3813530-A1 | COMPOSITIONS FOR ATTRACTING PESTS AND USES THEREOF | Domobios (BE) | 2021-05-05 | — | — | EP | disclosed |
| US-20200344991-A1 | METHOD AND DEVICE TO TRAP ACARIDS | DOMOBIOS (BE) | 2020-11-05 | — | — | US | disclosed |
| EP-3253203-B1 | METHOD AND DEVICE TO TRAP ACARIDS | DOMOBIOS (BE) | 2020-10-28 | — | — | EP | disclosed |
| US-20180027793-A1 | METHOD AND DEVICE TO TRAP ACARIDS | DOMOBIOS (BE) | 2018-02-01 | — | — | US | disclosed |
| US-9447134-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| WO-2016124566-A1 | METHOD AND DEVICE TO TRAP ACARIDS | DOMOBIOS (BE) | 2016-08-11 | — | — | WO | disclosed |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| CN-102532020-B | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives | REXAHN PHARMACEUTICALS INC | 2015-02-25 | — | — | CN | disclosed |
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008063548-A2 | 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS | REXAHN PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1813596-A1 | PROCESS FOR PRODUCING ALPHA, ALPHA- DIFLUOROAMINE | National University Corporation Hokkaido University (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6447801-B1 | COMPRISING LIPOSOMES HAVING PHOSPHOTIDE MEMBRANES ENCLOSING WATER SOLUBLE ANTHELMINTIC DRUGS USED AS INSECT REPELLANTS AND FOR PREVENTION OF SCHISTOSOMIASIS | SALAFSKY BERNARD (US) | 2002-09-10 | — | — | US | disclosed |
| EP-0963198-A4 | ANTI-PARASITIC ACTION OF N,N-DIETHYL-m-TOLUAMIDE (DEET) AND FORMULATIONS THAT PROLONG ITS ACTIVITY IN THE SKIN | SALAFSKY BERNARD (US) | 2001-08-29 | — | — | EP | disclosed |
| CN-1253774-A | Antiparasitic composition containing N, N-diethyl-m-toluamide | BONERDER SARAFSKI (US) | 2000-05-24 | — | — | CN | disclosed |
| EP-0963198-A1 | ANTI-PARASITIC ACTION OF N,N-DIETHYL-m-TOLUAMIDE (DEET) AND FORMULATIONS THAT PROLONG ITS ACTIVITY IN THE SKIN | Salafsky, Bernard (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998034604-A1 | ANTI-PARASITIC ACTION OF N,N-DIETHYL-m-TOLUAMIDE (DEET) AND FORMULATIONS THAT PROLONG ITS ACTIVITY IN THE SKIN | SALAFSKY BERNARD (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | FANCD2, NRAS, CCND2 | HPGD 204/4885TDP1 1459/4885SMN1; SMN2 4489/4885 |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | IMPDH1, IMPDH2, IMPA1 | HPGD 45/4885TDP1 2345/4885SMN1; SMN2 4091/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | HPGD 77/4885TDP1 737/4885SMN1; SMN2 1795/4885 |
| US-20210161130-A1 | COMPOSITIONS FOR ATTRACTING PESTS AND USES THEREOF | ACAT1, ATL3, NISCH | HPGD 4312/4885TDP1 4207/4885SMN1; SMN2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.